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PPediatric Pulmonary Hypertension
ffects of Long-Term Bosentan in
hildren With Pulmonary Arterial Hypertension
rika Berman Rosenzweig, MD,* D. Dunbar Ivy, MD,† Allison Widlitz, MS, PA,*
imee Doran, RN, MS, CPNP,† Lori R. Claussen, RN,† Delphine Yung, MD,* Steven H. Abman, MD,†
dele Morganti, PHD,‡ Ngoc Nguyen, BS,‡ Robyn J. Barst, MD*
ew York, New York; Denver, Colorado; and Allschwil, Switzerland
OBJECTIVES This study investigated the long-term outcome of children with pulmonary arterial hyper-
tension (PAH) treated with bosentan therapy, with or without concomitant prostanoid
therapy.
BACKGROUND Bosentan, an oral endothelin ETA/ETB receptor antagonist, improves hemodynamics and
exercise capacity in adults with PAH; however, limited data are available on its long-term
effects in children.
METHODS In this retrospective study, 86 children with PAH (idiopathic, associated with congenital
heart or connective tissue disease) started bosentan with or without concomitant intravenous
epoprostenol or subcutaneous treprostinil therapy. Hemodynamics, World Health Organi-
zation (WHO) functional class, and safety data were collected.
RESULTS At the cutoff date, 68 patients (79%) were still treated with bosentan, 13 (15%) were
discontinued, and 5 (6%) had died. Median exposure to bosentan was 14 months. In 90% of
the patients (n  78), WHO functional class improved (46%) or was unchanged (44%) with
bosentan treatment. Mean pulmonary artery pressure and pulmonary vascular resistance
decreased (64 3 mm Hg to 57 3 mm Hg, p 0.005 and 20 2 U · m2 to 15 2 U · m2,
p  0.01, respectively; n  49). Kaplan-Meier survival estimates at one and two years were
98% and 91%, respectively. The risk for worsening PAH was lower in patients in WHO
functional class I/II at bosentan initiation than in patients in WHO class III/IV at bosentan
initiation.
CONCLUSIONS These data suggest that bosentan, an oral endothelin ETA/ETB receptor antagonist, with or
without concomitant prostanoid therapy, is safe and efficacious for the treatment of PAH in
children. (J Am Coll Cardiol 2005;46:697–704) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.066Cardiology Foundation
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wulmonary arterial hypertension (PAH) is a rare condition
haracterized by extensive remodeling of the pulmonary
asculature, resulting in right heart failure and death if
ntreated. In infants and children, the most common forms
f PAH include persistent pulmonary hypertension of the
ewborn, idiopathic pulmonary arterial hypertension
See page 705
IPAH, also referred to as primary pulmonary hyperten-
ion), and pulmonary hypertension associated with congen-
tal heart disease (CHD) or chronic lung disease (1). In
eneral, the histopathologic changes are similar in children
nd in adults, although a spectrum of diseases associated
ith PAH and other clinical differences have been reported
1). Before the introduction of long-term vasodilator ther-
From the *Division of Pediatric Cardiology, New York Presbyterian Hospital, New
ork, New York; †University of Colorado Health Sciences Center and Pediatric
eart Lung Center, Children’s Hospital, Denver, Colorado; and ‡Actelion Pharma-
euticals Ltd., Allschwil, Switzerland. This research was supported by grant number
01 RR00069, General Clinical Research Centers Program, National Center for
esearch Resources, National Institutes of Health; and by Actelion Pharmaceuticals Ltd.i
Manuscript received September 9, 2004; revised manuscript received January 6,
005, accepted January 11, 2005.py, the prognosis for children with IPAH was poor, with a
edian survival of 0.8 years compared with 2.8 years in
dults (2,3). However, in IPAH a greater percentage of
hildren (40%) than adults (10%) are acutely responsive
o vasodilator testing and can be effectively treated, at least
nitially, with chronic oral calcium channel blockade (4).
Continuous intravenous infusion of epoprostenol appears
o be at least as effective in children with PAH as in adults
ith respect to improving hemodynamics and relieving
ymptoms (4,5). However, intravenous epoprostenol, owing
o its delivery system via central venous access, poses a
articular challenge for active pediatric patients who may
equire frequent central venous line replacements because of
islodgement and/or infection (1). Epoprostenol also has a
umber of side effects (e.g., jaw pain, headache, nausea,
iarrhea, foot pain, and leg pain) (6) that, although often
ot medically significant, adversely affect a child’s overall
uality of life. Potentially fatal complications include sepsis
elated to the intravenous delivery system and rebound
ulmonary hypertension following acute withdrawal (6).
urthermore, intravenous epoprostenol requires cooperation
uring its administration, which may be difficult to obtain
ith children. The prostacyclin analog, treprostinil (admin-stered via continuous subcutaneous infusion), improves
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Long-Term Bosentan in Pediatric PAH August 16, 2005:697–704xercise capacity and hemodynamics in both adults and
hildren with PAH; however, pain at the site of infusion has
requently been reported (7) and may be especially trouble-
ome for children. Thus, although chronic prostanoid ther-
py has proven safe and effective in PAH, due to its route(s)
f administration (i.e., intravenous or subcutaneous) and
ide effects, alternative therapies hold particular appeal for
ediatric patients. However, although new therapies for
AH produce sustained clinical and hemodynamic im-
rovement in adults (7–9), limited data are available regard-
ng their use in children.
Endothelin (ET) appears to be a key pathogenic mediator
n PAH (10,11). ET-1 mediates a variety of cellular
rocesses including hypertrophy, fibrosis, and inflammation,
n addition to being a potent vasoconstrictor and vascular
mooth-muscle mitogen (12). Endothelin-1 is present in
levated concentrations in the plasma and lung tissue of
dult (10,11) and pediatric (13,14) patients with PAH,
hich may adversely affect the pulmonary vascular bed,
roviding a rationale for ET receptor antagonism as a
argeted approach for the treatment of PAH. Bosentan, an
ral endothelin ETA/ETB receptor antagonist, improves
xercise capacity, hemodynamics, and time to clinical wors-
Abbreviations and Acronyms
b.i.d.  twice daily
CHD  congenital heart disease
CI  cardiac index
IPAH  idiopathic pulmonary arterial hypertension
PAH  pulmonary arterial hypertension
PAPm  mean pulmonary artery pressure
PVRI  pulmonary vascular resistance index
RAPm  mean right atrial pressure
WHO  World Health Organization
igure 1. Pediatric Pulmonary Arterial Hypertension (PAH) Treatment
ulmonary artery pressure; 2) no change or an increase in cardiac index; a
ystemic vascular resistance in response to vasodilator testing. †When bosentan
right heart failure.ning in adult patients with PAH (15,16) as well as survival
n IPAH (17). However, data on bosentan therapy for PAH
n children are extremely limited. In an open-label study
nvolving 19 children with PAH, the safety and efficacy of
osentan appeared comparable to results previously reported
n adult patients with PAH (18). In the present study,
linical experience from two PAH centers involving 86
ediatric patients with PAH (idiopathic, associated with
HD or connective tissue disease) who received bosentan
herapy was pooled to assess the safety and long-term effects
f bosentan treatment on functional capacity, hemodynam-
cs, and survival in children with PAH. The addition of
osentan to long-term prostanoid therapy was also
valuated.
ATIENTS AND METHODS
atients. From May 2001 to April 2003, a cohort of 86
ediatric patients (under 18 years of age) with PAH in
orld Health Organization (WHO) functional classes (as
odified by the New York Heart Association [19]) I to IV
ere treated with bosentan with or without concomitant
ntravenous epoprostenol or subcutaneous treprostinil ther-
py at two centers: the New York Presbyterian Hospital in
ew York, New York; and the Children’s Hospital in
enver, Colorado. The guidelines for treatment of the
atients with bosentan for both centers are illustrated in
igure 1. Intravenous epoprostenol or subcutaneous trepro-
tinil were added for patients who had clinically significant
eterioration despite treatment with bosentan. Pulmonary
rterial hypertension was either idiopathic or associated with
HD or connective tissue disease and was defined as PAH
ith a mean pulmonary artery pressure25 mm Hg at rest,
ulmonary capillary wedge pressure 15 mm Hg, and
ulmonary vascular resistance 3 U · m2. Patients with
elines. *“Acute responder” was defined as: 1) 20% decrease in mean
no change or a decrease in the ratio of pulmonary vascular resistance toGuid
nd 3)became available (April 2001). CCB  calcium channel blockade; RHF
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August 16, 2005:697–704 Long-Term Bosentan in Pediatric PAHHD included those with repaired (n 19) and unrepaired
n  25) or partially repaired (n  4) defects. Twenty-four
atients were included in previously published studies
18,20,21). Patients were enrolled following Institutional
eview Board approval, informed consent, and assent where
ppropriate.
reatment regimen. Bosentan treatment was initiated and
osed according to a previously published regimen (18). The
arget dose was 31.25 mg twice daily (b.i.d.) for children
eighing 10 to 20 kg, 62.5 mg b.i.d. for children weighing
0 to 40 kg, and 125 mg b.i.d. for children weighing 40
g. Three children weighed 10 kg at bosentan treatment
nitiation and received 15.6 mg b.i.d. One-half of the target
ose was administered daily during the first four weeks of
reatment and increased to target dose if bosentan was well
olerated. The dose of concomitant intravenous epoproste-
ol or subcutaneous treprostinil was adjusted according to
he investigators’ clinical judgment.
tudy assessments. The WHO functional class was as-
essed by four investigators before starting bosentan treat-
ent and during follow-up at least eight weeks after starting
osentan (patients who died were assigned functional class
V) (Appendix). Patients who were too young to classify (n
8) were not included in this assessment. Cardiopulmo-
ary hemodynamic parameters (cardiac index [CI], mean
ulmonary artery pressure [PAPm], pulmonary vascular
esistance index [PVRI], and mean right atrial pressure
RAPm]) were determined by cardiac catheterization within
he three-month period preceding bosentan initiation and at
east eight weeks after starting bosentan treatment. Acute
ulmonary vasoreactivity was assessed with intravenous
poprostenol or inhaled nitric oxide. Acute vasoreactivity
as defined as the combination of all three of the following
riteria: 1) 20% decrease in mean pulmonary artery
able 1. Demographic Characteristics at Bosentan Initiation
All Pat
(n 
ale/female, n (%) 37 (43%)/4
ge, yrs [range]
At bosentan initiation 11  5 [
At diagnosis 5  5 [
eight, kg [range] 34  16
tiology of pulmonary arterial hypertension, n (%)
Idiopathic 36 (42
CHD§ 48 (56
Connective tissue disease 2 (2%
HD status, n
Repaired 19
Unrepaired 24
Residual defect 5
cute vasoreactivity, n (%) 14 (16
HO functional class I/II/III/IV, n (%)¶ 6/34/32/6 (8
alues are number (percentage) of patients or mean  SD [range]. *Nine months; †1
eptal defect, ventricular septal defect, patent ductus arteriosus, transposition of t
esponsiveness to acute testing with intravenous epoprostenol or inhaled nitric oxide. ¶All
CHD  congenital heart disease; WHO  World Health Organization.ressure; 2) no change or an increase in CI; and 3) no
hange or a decrease in the ratio of pulmonary vascular
esistance to systemic vascular resistance (22). However, for
atients with congenital unrestrictive systemic to pulmonary
hunts (e.g., large ventricular septal defect or patent ductus
rteriosus), acute vasoreactivity was defined as: 1) 20%
ecrease in pulmonary vascular resistance; 2) no change or
n increase in CI; and 3) no change or a decrease in the ratio
f pulmonary vascular resistance to systemic vascular
esistance.
Safety was evaluated by adverse event reports. Clinical
nd laboratory variables were routinely monitored. Hepatic
ransaminase levels were checked every two weeks for the
rst two months and monthly thereafter. In adults, the
tandard threshold for hepatic transaminase abnormality is
3 times the upper limit of normal (ULN). For pediatric
atients, a conservative approach was applied, and hepatic
ransaminase elevations of 2 times ULN were reported.
tatistical methods. Due to the retrospective nature of the
ata collection, statistical testing was performed in an
xploratory fashion. The observed p values were compared
ith the standard 0.05 two-sided nominal type I error. The
umber of patients who improved in WHO functional class
rom bosentan initiation to last follow-up evaluation was
nalyzed by McNemar test (class I/II vs. III/IV). Changes
rom baseline to the last follow-up assessment of hemody-
amic variables were analyzed by single-sample t test.
Survival, assessed from starting bosentan treatment to
eath/data cutoff date, was summarized using Kaplan-
eier estimates and 95% confidence limits of the event-free
urvival at relevant time points.
Multivariate model building based on backward selection
rocess, with a selection level of 0.0157 (23), and the Cox
roportional-hazards model were performed to explore the
Concomitant Prostanoid
Patients Without
(n  42)
Patients With
(n  44)
%) 16 (38%)/26 (62%) 21 (48%)/23 (52%)
] 10  6 [0*–18] 12  4 [4–18]
] 5  5 [0‡–15] 5  5 [0†–16]
] 31  16 [5–64] 37  16 [14–89]
11 (26%) 25 (57%)
30 (71%) 18 (41%)
1 (2%) 1 (2%)
15 4
12 12
3 2
8 (19%) 6 (14%)
1/8) 2/18/14/4 (5/47/37/11) 4/16/18/2 (10/40/45/5)
h; ‡3 months. §Congenital heart defects included atrial septal defect, atrioventricular
at arteries, single ventricle, and double inlet left ventricle. Acute vasoreactivity:ients
86)
9 (57
0*–18
0†–16
[5–89
%)
%)
)
%)
/43/4
mont
he grepatients (n  78); without prostanoid (n  38); with prostanoid (n  40).
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Long-Term Bosentan in Pediatric PAH August 16, 2005:697–704otential effect of selected risk factors on time to worsening
f PAH. Time to PAH worsening was defined as the time
rom bosentan initiation to the first occurrence of worsening
AH requiring additional or alternative therapy for PAH
intravenous epoprostenol, subcutaneous treprostinil, oral
ildenafil) or atrial septostomy, transplantation, or death.
he selected risk factors recorded at bosentan initiation
ncluded gender, age at diagnosis, etiology (IPAH vs.
ther), acute pulmonary vasoreactivity (acute responder vs.
onresponder), WHO functional class (class I/II vs. III/IV),
onotherapy at bosentan initiation (bosentan with or with-
ut concomitant prostanoid therapy), and hemodynamic
ariables (CI, PAPm, PVRI, and RAPm). When we inves-
igated the effects of potential risk factors that have been
easured on a quantitative scale, we categorized the value of
hese factors in two groups using the observed mean as a
utoff point. Sensitiveness analysis was performed by apply-
ng the backward selection process and considering all
elected risk factors except hemodynamic variables, which
ere assessed in only 62 patients. In addition, the model-
uilding process was applied, including all the factors that
ere significant at the 0.1 level in the univariate Cox
egression (24).
able 2. Concomitant Medications at Bosentan Initiation
Concomitant Prostanoid*
All
Patients
(n  86)
Patients
Without
(n  42)
Patients
With
(n  44)
CBs 20 (23%) 18 (43%) 2 (5%)
nticoagulants 69 (80%) 33 (79%) 36 (82%)
iuretics 46 (53%) 15 (36%) 31 (70%)
DE inhibitors 20 (23%) 9 (21%) 11 (25%)
-arginine 5 (6%) 3 (7%) 2 (4%)
xygen as needed 46 (53%) 24 (57%) 22 (50%)
alues are number (percentage) of patients. *At study initiation: intravenous epopro-
tenol (n  36); subcutaneous treprostinil (n  8).
CCBs  calcium channel blockers; PDE  phosphodiesterase.
able 3. Cardiopulmonary Hemodynamic Parameters at Bosentan
ith Bosentan
All Patients
(n  49)
Baseline Change
APm (mm Hg) 64  3 7  2*
CWPm (mm Hg)† 9  1 1  1
APm (mm Hg) 7  1 0  1
I† (l/min/m2) 3.8  0.2 0.0  0.2
VRI (U · m2) 19  2 4  2*
VRI† (U · m2) 21  1 2  1
VRI/SVRI† 0.9  0.1 0.1  0.1
APm (mm Hg) 77  2 5  2
alues are given as mean  SEM for evaluable patients (i.e., patients with valid asse
 49). *p  0.05 (single-sample t test). †All patients (n  45); without prostano
CI  cardiac index; PAPm  mean pulmonary artery pressure; PCWPm  mean pulm
mean right atrial pressure; SAPm  mean systemic arterial pressure; SVRI  systemicESULTS
cohort of 86 children with PAH started bosentan therapy
etween May 2001 and April 2003, with follow-up through
ugust 2003. The median exposure time to bosentan up to
he cutoff date of August 2003 was 14 months (range 2 to
8 months).
emographic characteristics at bosentan initiation. De-
ographic characteristics at bosentan initiation are shown
n Tables 1 and 2. Patients ranged in age from 9 months to
8 years (11 5 years; mean SD) at the start of bosentan
herapy and were 5  5 years (mean  SD) of age at the
ime of PAH diagnosis. The subgroups of patients who
tarted bosentan with or without concomitant prostanoid
herapy (intravenous epoprostenol or subcutaneous trepro-
tinil) at bosentan initiation had somewhat different char-
cteristics. In the subgroup starting bosentan without pro-
tanoid therapy, PAH associated with CHD was more
requent than IPAH, and the percentage of repaired con-
enital heart defects was also higher. The subgroups also
iffered in concomitant treatment with calcium channel
lockers (i.e., 43% of patients in the subgroup starting
osentan without concomitant prostanoid therapy were
eing treated with calcium channel blockade therapy versus
% in the subgroup with concomitant prostanoid therapy).
t bosentan initiation, although functional class distribu-
ion was similar in both groups, hemodynamic parameters
ere consistent with more severe disease in the subgroup
tarting bosentan with concomitant prostanoid therapy
Table 3). At bosentan initiation, in the subgroup already
eceiving concomitant prostanoid therapy, median exposure
o intravenous epoprostenol was 48 months (range 2 days to
15 months) and median exposure to subcutaneous trepro-
tinil was 31 months (range 19 to 41 months).
HO functional class. Seventy-eight patients (38 in the
ubgroup starting bosentan without concomitant prostanoid
herapy and 40 in the subgroup with concomitant prosta-
oid therapy) had WHO functional class assessments at
tiation and After at Least Eight Weeks of Treatment
Concomitant Prostanoid
Patients Without
(n  25)
Patients With
(n  24)
seline Change Baseline Change
 3 9  3* 68  5 4  3
 1 0  1 9  1 2  1
 0.4 1  1 8  1 0  1
 0.3 0.1  0.3 3.9  0.3 0.1  0.4
 2 5  1* 21  3 3  3
 2 3  2 20  2 2  2
 0.1 0.2  0.1* 0.9  0.1 0.1  0.1
 3 5  2 76  3 6  3
s at study initiation (baseline) and after at least 8 weeks of treatment with bosentan,
23); with prostanoid (n  22).Ini
Ba
59
9
6
3.7
18
21
0.8
76
ssment
id (n onary capillary wedge pressure; PVRI  pulmonary vascular resistance index; RAPm
vascular resistance index.
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August 16, 2005:697–704 Long-Term Bosentan in Pediatric PAHosentan initiation and at follow-up (at least eight weeks
fter the initiation of bosentan treatment (Appendix). The
edian follow-up of these patients was 12 months (range 3
o 25 months).
Overall, 36 patients (46%) improved by at least one class
p  0.001; 5 of these improved by 2 functional classes), 34
atients (44%) remained in the same functional class, and 8
10%) worsened by one class (Fig. 2). Although not statis-
ically significant, the improvement appeared more pro-
ounced for the patients who started bosentan without
oncomitant prostanoid therapy than for those treated with
osentan and concomitant prostanoid therapy.
ardiopulmonary hemodynamics. Forty-nine patients
25 in the subgroup starting bosentan without concomitant
rostanoid therapy and 24 in the subgroup with concomi-
ant prostanoid therapy) had hemodynamic assessments
ithin the three-month period preceding bosentan initia-
ion and at follow-up (i.e., at least eight weeks after the
nitiation of bosentan treatment) (Table 3). The median
ollow-up of these patients was 9 months (range 3 to 28
onths). Overall, PAPm decreased from 64 3 mm Hg to
7  3 mm Hg (mean  SEM, n  49; p  0.005).
ulmonary vascular resistance decreased from 20  2
· m2 to 15 2 U · m2 (mean SEM, n 49; p 0.01);
I was unchanged. For the children receiving bosentan
ithout concomitant prostanoid therapy versus the patients
eceiving bosentan with concomitant prostanoid therapy,
APm decreased 9  3 mm Hg versus 4  3 mm Hg
mean  SEM) and PVRI decreased 6  1 U · m2 versus
3  3 U · m2 (mean  SEM), respectively.
reatment status and survival. Sixty-five (76%) of the 86
hildren were followed for at least one year. Patient survival
nd treatment status after one year of treatment with
osentan are shown in Figure 3. Among the 33 patients who
tarted bosentan without concomitant prostanoid therapy at
osentan initiation and were followed for at least one year,
5 (76%) continued bosentan without requiring additional
herapy, 4 (12%) continued bosentan with additional PAH
reatment started (3 intravenous epoprostenol, 1 oral silde-
afil), 3 (9%) discontinued bosentan, and 1 (3%) died.
mong the 32 patients who started bosentan with concom-
igure 2. World Health Organization functional class at bosentan initia-
ion and after at least eight weeks of treatment with bosentan. (Patients
ho died were assigned functional class IV.)tant prostanoid therapy at bosentan initiation and were
t
(ollowed for at least one year, 27 (84%) continued bosentan,
(13%) discontinued bosentan, and 1 (3%) died. The other
hree patients who died started receiving bosentan after
ugust 2002, which was 1 year before the data cutoff of
ugust 2003 (i.e., they were followed and treated for less
han one year), making long-term assessment difficult.
At data cutoff date, 68 of the 86 patients (79%) continued
osentan. Eleven of these 68 patients received additional
AH treatment (intravenous epoprostenol, oral sildenafil,
r atrial septostomy): 10 patients had failed treatment with
osentan and 1 patient had oral sildenafil added despite
oing well clinically. Thirteen of the 86 patients (15%)
iscontinued bosentan because of: increase in hepatic
ransaminases (n  3), other adverse events (n  4), or
reatment failure (alternative PAH treatment or transplan-
ation; n  6). Five of the 86 patients (6%) died (Table 4).
atient survival and treatment status in both subgroups were
omparable. Overall, the dose for the 36 children treated
ith concomitant intravenous epoprostenol decreased from
able 4. Patient Survival and Treatment Status at Data
utoff Date
Concomitant
Prostanoid
All
Patients
(n  86)
Patients
Without
(n  42)
Patients
With
(n  44)
ontinued bosentan
treatment, n (%)
68 (79%) 35* (83%) 33† (75%)
iscontinuation, n (%)
Increase in liver enzymes 3 (3%) 2 (5%) 1 (2%)
Other adverse event 4 (5%) 2 (5%) 2 (4%)
Treatment failure‡ 6 (7%) 1 (2%) 5 (11%)
eaths, n (%) 5 (6%) 2 (5%) 3 (7%)
alues are number (percentage) of patients. *Six patients were considered treatment
ailure and required additional treatments (intravenous epoprostenol or oral silde-
afil). †Five patients received additional treatments: 4 patients were considered
reatment failure (atrial septostomy or oral sildenafil), 1 patient received oral sildenafil
igure 3. Patient survival and treatment status at one year of treatment
ith bosentan (i.e., these patients were started before August 2002; 1
ear before the data cutoff date, August 2003).o optimize therapy. ‡Treatment failure: requiring additional or alternative treatment
i.e., intravenous epoprostenol, oral sildenafil, atrial septostomy, or transplantation).
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Long-Term Bosentan in Pediatric PAH August 16, 2005:697–7043  42 ng/kg/min (mean  SD) at bosentan initiation to
8  43 ng/kg/min at data cutoff date; the dose for the 8
atients treated with concomitant subcutaneous treprostinil
as 59 26 ng/kg/min (mean SD) at bosentan initiation
nd 59  32 ng/kg/min at data cutoff date.
Summary statistics on survival for the 86 patients are
hown in Figure 4. Kaplan-Meier estimates of survival at
ne and two years were 98% and 91%, respectively. In the
ubgroup starting bosentan without concomitant prostanoid
herapy, the one- and two-year survival estimates were 98%
nd 94%, respectively, whereas in the subgroup receiving
oncomitant prostanoid therapy, the one- and two-year
urvival estimates were 98% and 89%, respectively. In the
ubgroup of patients with IPAH (with and without con-
omitant prostanoid therapy), the one- and two-year sur-
ival estimates were 100% and 88%, respectively, whereas in
he subgroup with PAH associated with CHD (with and
ithout concomitant prostanoid therapy), the one- and
wo-year survival estimates were the same at 96%.
afety and tolerability. The most frequent adverse event
as peripheral edema (n  7, 8%). Systemic hypotension
as reported in three patients (3%). Fatigue leading to
iscontinuation was observed in two patients (2%) 9 and 11
onths after starting bosentan, which resolved following
igure 4. Kaplan-Meier estimates of survival. Median survival follow-up
as 15 months (range 3 to 28 months) in the entire bosentan-treated
roup, 15 months (range 3 to 28 months) in the bosentan subgroup
ithout concomitant prostanoid therapy, and 16 months in the bosentan
ubgroup with concomitant prostanoid therapy (range 5 to 27 months).
Table 5. Multivariate Analysis Relating Time
Risk Factor
Model
Hazard Rat
[95% CI]
WHO functional class III to IV 7.33 [2.16–24
Model fit Number o
Wald teCI  confidence interval; PAH  pulmonary arterial hypertensioniscontinuation of bosentan, and two patients (2%) with
nrepaired CHD discontinued bosentan 5 and 7 months
fter starting bosentan because of systemic arterial oxygen
esaturation. The systemic arterial oxygen saturation re-
urned to baseline following discontinuation of bosentan in
ne of these two patients.
Asymptomatic increases in liver transaminases (above 2
LN) were reported in 10 patients (12%). No patients had
ymptomatic increases in liver transaminases. Of the 10
atients who had asymptomatic increases in liver transami-
ases, 7 (8%) had an elevation of two to three times ULN
2 of the 7 patients discontinued bosentan), 1 (1%) had an
levation three to five times ULN, and 2 (2%) had an
levation five to eight times ULN (1 patient discontinued
osentan). The elevation in liver transaminases resolved in
he seven patients (8%) that continued treatment with
osentan.
Five patients died during the study. Three patients in the
ubgroup starting bosentan with concomitant prostanoid
herapy died: two from hemoptysis and acute respiratory
istress syndrome, and one from worsening right heart
ailure. Two patients in the subgroup starting bosentan
ithout prostanoid therapy died from right heart failure. All
eaths were considered as due to the clinical progression of
AH.
isk factors associated with the time to PAH worsening.
able 5 summarizes the results of the multivariate analysis
f the effect of selected risk factors assessed at bosentan
nitiation on time to PAH worsening. Two separate models
ith a backward selection level of 0.0157 were performed
ncluding (n  81) or excluding (n  62) the patients
ithout hemodynamic assessments at bosentan initiation.
he hazard ratios obtained from each model (with and
ithout hemodynamics) were similar, and the inclusion of
emodynamic parameters led to the selection of the same
rognostic factor (i.e., WHO functional class). The propor-
ional risk of PAH worsening was higher for patients in
HO functional classes III and IV at bosentan initiation
han in patients in WHO class I/II at bosentan initiation,
ut was not found to be significantly influenced by gender,
ge at diagnosis, etiology, acute vasoreactivity, bosentan
onotherapy, or hemodynamic variables. In the univariate
election process (Table 6), WHO functional classes III and
V at bosentan initiation and older age at diagnosis were
dentified for the final model. Although the hazard ratio of
HO functional class was comparable to the one observed
H Worsening to Risk Factors
 81) Model 2 (n  62)
p Value
Hazard Ratio
[95% CI] p Value
0.001 7.26 [1.64–32.23] 0.009
nts  21 Number of events  15
0.001 Wald test p  0.009to PA
1 (n
io
.90]
f eve
st p ; WHO  World Health Organization.
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onger statistically significant in the multivariate analysis.
ISCUSSION
ulmonary arterial hypertension is a progressive disease
ssociated with a poor prognosis in both children and adults
3,4,25). Despite increased knowledge regarding the natural
istory and clinical course of adult patients with PAH (1),
ata describing the response to treatment, including survival
n pediatric PAH patients, are limited. The present study
as a retrospective analysis of clinical data that involved a
arge cohort of children with PAH (IPAH or PAH associ-
ted with CHD or connective tissue disease), thereby
roviding a fairly extensive experience of long-term safety
nd efficacy of bosentan for the treatment of pediatric PAH
ith or without concomitant prostanoid treatment.
Among the 78 pediatric patients with baseline and
ollow-up WHO functional class assessments, 70 patients
90%) either improved (36 patients, 46%) or were un-
hanged (34 patients, 44%) as assessed by WHO functional
lass, consistent with clinical benefit for the overall popula-
ion treated with bosentan. The observed improvement in
emodynamic parameters was similar to that previously
eported in a small, 12-week open-label study with bosentan
n children with IPAH or PAH associated with CHD
excluding patients with the classic Eisenmenger syndrome)
18). The improvements in WHO functional class and
emodynamics were more pronounced for the children who
tarted bosentan without concomitant prostanoid therapy
han for those treated with bosentan and prostanoid ther-
py. However, the patients who needed prostanoid treat-
ent before bosentan initiation appeared to have more
dvanced disease, as suggested by their hemodynamic pa-
ameters at bosentan initiation. For these children, addi-
ional benefit with bosentan may have been lessened by
revious improvement with prostanoid therapy.
Children with PAH often have a different hemodynamic
rofile and response to treatment than adults. As observed
n other pediatric studies (3), the PAH children in this study
ad a higher CI at bosentan initiation compared with their
dult counterparts. This may account for the lack of increase
n CI with treatment with bosentan, which is in contrast
ith the increase in CI reported for adult PAH patients
Table 6. Cox Modeling Based on Risk Factors
Time to PAH Worsening
Risk Factor
Final Adjusted M
Hazard Ratio [95
WHO functional class III to IV 6.76 [1.96–23.
Age at PAH diagnosis 1.47 [0.62–3.5
*The final adjusted model including WHO functional class I
0.0042. †Unadjusted models are univariate models including
CI  confidence interval; PAH  pulmonary arterial hy15,26). However, PAPm, which tended to be higher at paseline for children with PAH than for adults with PAH,
mproved with bosentan treatment to a greater degree in
hildren than in previous reports with adult patients (15,26).
The safety profile of bosentan in children with PAH was
imilar to that previously reported with adult patients
15,26). However, there were also two cases of fatigue and
wo cases of systemic arterial oxygen desaturation, with both
ases of desaturation occurring in patients with unrepaired
ongenital heart defects.
As the dose of intravenous epoprostenol was adjusted
ased on the clinical investigator’s discretion, whether it can
e reduced in combination with bosentan could not be
etermined from this retrospective study. However, this has
een previously reported (20) for eight IPAH children
ncluded in the present study who were in stable condition
n intravenous epoprostenol for more than one year. The
ddition of bosentan therapy allowed for a reduction of
he intravenous epoprostenol dose, which decreased
poprostenol-associated side effects without apparent clini-
al or hemodynamic worsening. In three of these children,
ith the addition of bosentan, the epoprostenol was discon-
inued with maintenance of hemodynamics for up to one
ear. In a recent study with adult PAH patients (21), the
ombination of oral bosentan and intravenous epoprostenol
herapy was evaluated in comparison with intravenous
poprostenol alone. Unfortunately, perhaps because of the
mall sample size, statistically significant differences were
ot observed. In practice, although bosentan and intrave-
ous epoprostenol have been prescribed simultaneously,
dditional clinical data are necessary to evaluate the overall
afety and efficacy of the combination (27).
The present study reports survival rates after one and two
ears of bosentan treatment with or without concomitant
rostanoid therapy (respectively 98% and 91% for all etiol-
gies, 100% and 88% for IPAH, and 96% at one and two
ears for PAH-CHD). In the present study, PAH worsen-
ng was strongly related to WHO functional class at
osentan initiation, independent of PAH etiology. Patients
n WHO functional classes I and II at the start of bosentan
herapy had a markedly lower occurrence of PAH worsen-
ng than did patients in functional classes III and IV at the
tart of bosentan therapy. In several IPAH studies, WHO
unctional classes III and IV have been associated with a
ecreased survival rate in both pediatric and adult PAH
cted in the Univariate Selection Process on
l (n  81)* Unadjusted Models†
] p Value Hazard Ratio [95% CI] p Value
0.0025 7.33 [2.16–24.90] 0.0014
0.39 2.12 [0.90–5.00] 0.09
and age at PAH diagnosis 5 years includes 21 events; p 
ingle covariate at a time.
sion; WHO  World Health Organization.Sele
ode
% CI
31]
0]
II–IVatients (2,3). Because a clinical deterioration is often
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Long-Term Bosentan in Pediatric PAH August 16, 2005:697–704ombined with a deteriorating hemodynamic status, it is not
urprising that the addition of hemodynamic variables did
ot significantly improve the model fit.
Although the risk for PAH worsening was significantly
ssociated with age at diagnosis by univariate analysis (i.e.,
he younger the child was at the time of diagnosis, the better
he outcome was), the age at diagnosis was no longer
ignificant once functional class was included in the model.
reater pulmonary vascular medial hypertrophy with less
ntimal fibrosis and fewer plexiform lesions have been
eported in young children in comparison to older PAH
atients (22). In addition, younger children have also been
eported to acutely respond with vasodilator testing more
ften than adult IPAH patients (3,4).
The main limitations of this study are its retrospective
esign and the lack of a control group. However, consider-
ng the limited clinical pediatric data currently available, the
resent retrospective study, which involves a large cohort of
hildren, provides clinical data consistent with long-term
afety and efficacy of bosentan for the treatment of pediatric
AH. The inclusion of patients with different PAH etiol-
gies (IPAH and PAH associated with CHD or connective
issue disease) could also be considered a limitation. How-
ver, these clinical conditions are known to share many
istopathologic, pathobiologic, and clinical similarities (19).
lthough the median follow-up for hemodynamics was
ine months and does not necessarily constitute “long-term”
ollow-up, we believe these data are meaningful given the
ack of previous hemodynamic data in children. Further-
ore, whereas the efficacy of bosentan in patients with
PAH has been demonstrated in adults (16), limited clinical
ata are available on the treatment of patients with PAH
ssociated with CHD. The data from the present study,
hich include a large proportion of patients with PAH
ssociated with CHD, suggests that bosentan may also
enefit these patients.
In conclusion, these data suggest that bosentan, an oral
ndothelin ETA/ETB receptor antagonist, with or without
oncomitant prostanoid therapy, is safe and efficacious for
he treatment of PAH in children.
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PPENDIX
or the WHO Functional Classification of Pulmonary
ypertension, please see the online version of this article.
